A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC)

Cancer Chemotherapy and Pharmacology

Volumn 60, Issue 1, 2007, Pages 81-89

  Cohen, Roger B ^a   Langer, Corey J ^a   Simon, George Rajan ^b   Eisenberg, Peter David ^c   Hainsworth, John Daniel ^d   Madajewicz, Stefan ^e   Cosgriff, Thomas Michael ^f   Pierce, Kristen ^g   Xu, Huiping ^g   Liau, Katherine ^g   Healey, Diane ^g  

^a FOX CHASE CANCER CENTER   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c California Cancer Care   (United States)

^d SARAH CANNON RESEARCH INSTITUTE   (United States)

^e STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

^f Hematology Oncology Specialists   (United States)

^g PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Angiogenesis; Carboplatin; NSCLC; Paclitaxel; Pharmacokinetics; Phase I; Tyrosine kinase inhibitor; VEGFR 2

Indexed keywords

3 (4 BROMO 2,6 DIFLUOROBENZYLOXY) 5 [3 [4 (1 PYRROLIDINYL)BUTYL]UREIDO] 4 ISOTHIAZOLECARBOXAMIDE; CARBOPLATIN; PACLITAXEL;

ABNORMAL VISION; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; DYSPNEA; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HEMATURIA; HUMAN; HYPERTENSION; HYPOPHOSPHATEMIA; INDUCED HYPOTENSION; LUNG NON SMALL CELL CANCER; MALE; MOUTH ULCER; MUCOSAL DISEASE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RECTUM HEMORRHAGE; RECURRENT CANCER; SIDE EFFECT; STOMATITIS; SYNCOPE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; XEROPHTHALMIA;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EXANTHEMA; FEMALE; GASTROINTESTINAL DISEASES; HALF-LIFE; HEMATOLOGIC DISEASES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; PROGNOSIS; THIAZOLES; TREATMENT OUTCOME; UREA;

EID: 34247326880     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-006-0352-0     Document Type: Article

References (34)

1. Fontanini G et al (1997) Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. Clin Cancer Res 3(6):861-865
2. Yuan A et al (2000) Correlation of total VEGF mRNA and protein expression with histologic type, tumor angiogenesis, patient survival and timing of relapse in non-small-cell lung cancer. Int J Cancer 89(6):475-483
3. Tsao MS et al (1997) Angiogenesis correlates with vascular endothelial growth factor expression but not with Ki-ras oncogene activation in non-small cell lung carcinoma. Clin Cancer Res 3(10):1807-1814
4. Takahama M et al (1999) Enhanced expression of Tie2, its ligand angiopoietin-1, vascular endothelial growth factor, and CD31 in human non-small cell lung carcinomas. Clin Cancer Res 5(9):2506-2510
5. O'Byrne KJ et al (2000) Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. Br J Cancer 82(8):1427-1432
6. Koukourakis MI et al (2000) Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer. Cancer Res 60(11):3088-3095
7. Wong MP et al (2000) The angiopoietins, tie2 and vascular endothelial growth factor are differentially expressed in the transformation of normal lung to non-small cell lung carcinomas. Lung Cancer 29(1):11-22
8. Fontanini G et al (1997) Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study. J Natl Cancer Inst 89(12):881-886
9. Zeng H, Dvorak HF, Mukhopadhyay D (2001) Vascular permeability factor (VPF)/vascular endothelial growth factor (VEGF) peceptor-1 down-modulates VPF/VEGF receptor-2-mediated endothelial cell proliferation, but not migration, through phosphatidylinositol 3-kinase-dependent pathways. J Biol Chem 276(29):26969-22699
10. Millauer B et al (1993) High afinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 72(6):835-846
11. Herbst RS et al (2005) Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 23(11):2544-2555
12. Hurwitz H et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335-2342
13. Longo F, Mansueto G (2005) Bevacizumab combined with chemotherapy in the treatment of solid tumors: the novelty from ASCO 2005. Tumori 91(4):suppl 1-7
14. Wilhelm SM et al (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64(19):7099-7109
15. Hennequin L, Ple P, Stokes E (2004) Structure-activity relationship, physicochemical and pharmacokinetic properties of AZD2171: a highly potent inhibitor of VEGF receptor tyrosine kinases. Proc Am Assoc Cancer Res 45:1048
16. Wakelee HA, Schiller JH (2005) Targeting angiogenesis with vascular endothelial growth factor receptor small-molecule inhibitors: novel agents with potential in lung cancer. Clin Lung Cancer 7(Suppl 1):S31-S38
17. Rosen L, Mulay M, Long J (2003) Phase I trial of SU011248, a novel tyrosine kinase inhibitor in advanced solid tumors. Proc Am Soc Clin Oncol 22:191
18. Rugo HS et al (2005) Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 23(24): 5474-5483
19. Veronese M, Flaherty R, Townsend A (2004) Pharmacodynamic study of the raf kinase inhibitor BAY 43-9006: Mechanisms of hypertension. Proc Am Soc Clin Oncol 22:135s
20. Schiller JH et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346(2):92-98
21. Sandler A et al (2005) Randomized phase II/III Trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC # 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) Trial-E4599 ASCO
22. Tolcher A et al (2002) A phase I study of an oral vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor, CP-547,632, in patients (pts) with advanced solid tumors. Proc Am Assoc Clin Oncol 21:84a
23. Miller AB et al (1981) Reporting results of cancer treatment. Cancer 47(1):207-214
24. Thall PF, Simon R, Ellenberg SS (1989) A two-stage design for choosing among several experimental treatments and a control in clinical trials. Biometrics 45(2):537-547
25. Sica DA (2006) Angiogenesis inhibitors and hypertension: an emerging issue. J Clin Oncol 24(9):1329-1331
26. Herbst RS et al (2004) Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 22(5):785-794
27. Giaccone G et al (2004) Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 22(5):777-784
28. Herbst RS et al (2005) TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23(25):5892-5899
29. Fuster LM, Sandler AB (2004) Select clinical trials of erlotinib (OSI-774) in non-small-cell lung cancer with emphasis on phase III outcomes. Clin Lung Cancer 6(Suppl 1):S24-S29
30. Hecht J (2005) A randomized double-blind placebo-controlled phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ ZK 222584 or placebo (CONFIRM-1)., in ASCO annual meeting
31. Beebe JS et al (2003) Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy. Cancer Res 63(21):7301-7309
32. Stopeck A et al (2002) Results of a Phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies. Clin Cancer Res 8(9):2798-2805
33. Thomas AL et al (2003) Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584. Semin Oncol 30(3 Suppl 6):32-38
34. George E, Michaelson D, Oh W (2003) Phase I study of PTK787/ZK 222584 (PTK/ZK) in metastatic renal cell carcinoma. Proc Am Soc Clin Oncol 22:385